Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study 3 of a transdermal physostigmine + hyoscine patch development program
ISRCTN16859029Phase 2Completed
- Sponsor
- Defence Science and Technology Laboratory
- Start
- Oct 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of physostigmine and scopolamine in nerve agent poisoning (6 arms), sponsored by Defence Science and Technology Laboratory. Primary endpoint: Safety and tolerability. Started Oct 2005; status: completed.
02
Drugs
physostigminescopolamine
03
Conditions
nerve agent poisoning
Beyond the preview
Go deeper on ISRCTN16859029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16859029.